Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 88,502 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for BAYRY. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: BAYRY is a Buy candidate.
BAYRY stock price ended at $11.05 on 星期一, after rising 0.73%
On the latest trading day Mar 23, 2026, the stock price of BAYRY rose by 0.73%, climbing from $11.18 to $11.05. During the session, the stock saw a volatility of 4.76%, with prices oscillating between a daily low of $10.92 and a high of $11.44. Notably, trading volume dropped by 321.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 974.4K shares were traded, equating to a market value of approximately $43.4B.